Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments.
Schepelmann
Silke
S
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, London, UK.
Spooner
Robert
R
Friedlos
Frank
F
Marais
Richard
R
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000633:toxicity; D001388:Aziridines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D024201:Bystander Effect; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D041722:Genes, Transgenic, Suicide / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005971:Glutamates / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D009601:Nitroreductases / Q000235:genetics* / Q000378:metabolism; D010051:Ovarian Neoplasms; D011355:Prodrugs / Q000493:pharmacokinetics* / Q000633:toxicity; D013347:Subcellular Fractions / Q000201:enzymology; D014162:Transfection / Q000379:methods; D014407:Tumor Cells, Cultured; D011623:gamma-Glutamyl Hydrolase / Q000235:genetics* / Q000378:metabolism*
D000970:Antineoplastic Agents; D001388:Aziridines; D005971:Glutamates; D009588:Nitrogen Mustard Compounds; D011355:Prodrugs; C092574:4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid; C100099:tretazicar; D009601:Nitroreductases; D011623:gamma-Glutamyl Hydrolase